Alnylam Pharmaceuticals | ALNY - Nettoeinkommen

Aktienkurs
318.55
Täglich Wechseln
-1.87 -0.58%
Monatlich
-6.13%
Jährlich
25.69%
Q1 Prognose
303.95




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Moderna USD -200M 625M 2025-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 3.93B 113M 2025-09
PTC Therapeutics USD -134.96M 150.86M 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Takeda JPY 103.64B 115.44B 2025-12
Tectonic Therapeutic USD -19.04M 940K 2025-09
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12
Xencor USD -6.65M 626K 2025-12